|1.||Sundy, John S: 11 articles (12/2014 - 01/2006)|
|2.||Baraf, Herbert S B: 8 articles (12/2014 - 09/2008)|
|3.||Becker, Michael A: 6 articles (12/2014 - 09/2008)|
|4.||Yood, Robert A: 5 articles (12/2014 - 08/2011)|
|5.||Ottery, Faith D: 4 articles (12/2014 - 01/2013)|
|6.||Ganson, Nancy J: 4 articles (01/2014 - 01/2006)|
|7.||Hershfield, Michael S: 4 articles (01/2014 - 01/2006)|
|8.||Kelly, Susan J: 4 articles (01/2014 - 01/2006)|
|9.||Edwards, N Lawrence: 4 articles (07/2012 - 08/2011)|
|10.||Huang, William: 4 articles (08/2011 - 03/2007)|
01/01/2014 - "This study showed pegloticase is probably beneficial in the management of tophi in gout, in terms of resolution of tophi, but with a high risk of adverse infusion reactions. "
09/01/2012 - "Two recent Phase III trials have found pegloticase to be effective in the management of treatment-failure gout. "
11/01/2011 - "For patients with refractory and tophaceous gout, intravenous pegloticase is a new treatment option. "
11/01/2011 - "For patients with refractory and tophaceous gout, intravenous pegloticase is a new treatment option."
07/01/2012 - "Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials."
01/01/2014 - "In 11 of 12 TR, pUox fell rapidly and hyperuricemia recurred before dose 2. In all TR and NR, loss of response to pegloticase was accompanied by Ab to PEG, which was pre-existing in half of those who had no prior exposure to pegloticase. "
07/01/2012 - "Pegloticase is effective in treating hyperuricemia and the clinical manifestations of gout in patients who cannot be adequately managed with conventional therapy."
07/15/1988 - "As an adjunct to cytolytic therapy for hematologic malignancies when protection from hyperuricemia is needed rapidly, PEG-uricase deserves further study."
06/01/2008 - "Population pharmacokinetic and pharmacodynamic analysis of pegloticase in subjects with hyperuricemia and treatment-failure gout."
01/03/2008 - "PEG-uricase in the management of treatment-resistant gout and hyperuricemia."
07/01/2012 - "Pegloticase therapy resulted in statistically significant and clinically meaningful improvements in PtGA, pain, physical function, and HRQOL."
07/01/2011 - "ES and SRMs in pegloticase group were as follows: VAS pain, 0.34 and 0.30; SF-36 pain, 0.69 and 0.57; patient global, 0.49 and 0.44. "
07/01/2011 - "Pegloticase group had significantly more improvement than placebo at 6 months, mean (SD): VAS pain, -9.2 (29.3) versus 1.9 (26.4), p=0.0002; SF-36 pain, 14.6 (25.6) versus -0.04 (21.1), p<0.0001; and patient global, -9.3 (26.5) versus 3.4 (22.8), p<0.0001. "
07/01/2013 - "The patient became wheel chair bound due to his pain and, at that point, the decision was made to initiate treatment with pegloticase. "
07/01/2012 - "To assess the efficacy of pegloticase on pain, physical function, and health-related quality of life (HRQOL) in patients with refractory chronic gout. "
|4.||Renal Insufficiency (Renal Failure)
01/01/2014 - "Patients with renal insufficiency were randomized to pegloticase 8 mg every 2 weeks (n = 42), pegloticase 8 mg every 4 weeks (n = 41), or placebo (n = 20) for 6 months as defined by the study protocols. "
12/01/2011 - "Uricolytic drugs (pegloticase), which are currently being investigated, may be useful for the treatment of serious gout with tophus, especially in the presence of renal failure. "
05/01/2015 - "Administration of pegloticase in patients with comorbid chronic tophaceous gout and endstage renal failure requiring hemodialysis appears feasible."
07/15/1988 - "We report the first clinical use of PEG-modified Arthrobacter protoformiae uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma and renal insufficiency who was allergic to allopurinol. "
|5.||Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
11/01/2012 - "In humans, anti-PEG may limit therapeutic efficacy and/or reduce tolerance of PEG-asparaginase (PEG-ASNase) in patients with acute lymphoblastic leukemia and of pegloticase in patients with chronic gout, but did not impair hyposensitization of allergic patients with mPEG-modified ragweed extract or honeybee venom or the response to PEG-IFN in patients with hepatitis C. "
|1.||Uric Acid (Urate)
|2.||Urate Oxidase (Uricase)
|3.||Polyethylene Glycols (Polyethylene Glycol)
|6.||monomethoxypolyethylene glycol (MPEG)
|9.||Interleukin-1 (Interleukin 1)
|10.||Ethylene Glycol (Monoethylene Glycol)
|4.||Renal Dialysis (Hemodialysis)
|5.||Wheelchairs (Wheel Chair)